Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Parallel Signaling through PI3K/AKT/mTOR Mediates Resistance to MEK Inhibition in Preclinical Models of Acute Myeloid Leukemia (AML): Synergistic Effects of Combined MEK and mTOR Inhibition.

Maria Rosaria Ricciardi, PhD, Twee Tsao, PhD, Stephen Lee Abrams, PhD, Paola Bergamo, MS, Linda S Steelman, BS., MS, Samantha Decandia, PhD, Lara Felicioni, PhD, Ludovica Ciuffreda, PhD, Cristina Di Sanza, PhD, Antonio Marchetti, MD, PhD, Francesco Cognetti, MD, James McCubrey, PhD, Marina Konopleva, MD, PhD, Michael Andreeff, MD, PhD, Agostino Tafuri, MD, Michele Milella, MD

Blood (2009) 114 (22): 594.

https://doi.org/10.1182/blood.V114.22.594.594

Published: 2009

Journal Articles

Development of Mek inhibition (MEK-I)-Based Therapeutic Strategies in Acute Myeloid Leukemia (AML)

Michele Milella, MD, Maria Rosaria Ricciardi, Paola Bergamo, MS, Maria Cristina Scerpa, PhD, Jacopo Gervasoni, MS, Maria Teresa Petrucci, MD, Sabina Chiaretti, MD, Simona Tavolaro, MS, Ludovica Ciuffreda, PhD, Samantha Decandia, Francesco Libotte, Stephen Lee Abrams, Linda S Steelman, BS., MS, Marina Konopleva, MD, PhD, Francesco Cognetti, MD, Robert Foa, Michael Andreeff, MD, PhD, James McCubrey, PhD, Agostino Tafuri

Blood (2008) 112 (11): 860.

https://doi.org/10.1182/blood.V112.11.860.860

Published: 2008

Journal Articles

Comparative Gene Profiling of Acute Myeloid Leukemia (AML) and Malignant Melanoma (MEL) Cell Lines Exposed to the MEK Inhibitor PD0325901 Reveals Common Effectors of the MEK/ERK Kinase Module.

Michele Milella, MD, Sabina Chiaretti, MD, PhD, Maria R. Ricciardi, PhD, Simona Tavolaro, BSc, Ludovica Ciuffreda, PhD, Barbara Benassi, PhD, Alfonso Bellacosa, MD, PhD, Gianfranco Peluso, PhD, Paola Bergamo, MS, James A. McCubrey, PhD, Francesco Cognetti, MD, Gabriella Zupi, PhD, Robert Foà, MD, Agostino Tafuri, MD

Blood (2007) 110 (11): 3470.

https://doi.org/10.1182/blood.V110.11.3470.3470

Published: 2007

Journal Articles

Molecular and Functional Effects of the Novel MEK Inhibitor PD0325901 in Preclinical Models of Human Leukemias.

Michele Milella, MD, Maria Rosaria Ricciardi, PhD, Chiara Gregorj, PhD, Fabiana De Cave, PhD, Steven L. Abrams, BS, Linda S. Steelman, MS, Sabina Chiaretti, PhD, Marina Konopleva, MD, PhD, Maria Teresa Petrucci, MD, Francesco Cognetti, MD, Robert Foa, MD, PhD, Michael Andreeff, MD, PhD, James McCubrey, PhD, Agostino Tafuri, MD

Blood (2006) 108 (11): 254.

https://doi.org/10.1182/blood.V108.11.254.254

Published: 2006

Journal Articles

MEK blockade converts AML differentiating response to retinoids into extensive apoptosis

Michele Milella, Marina Konopleva, Cristina M. Precupanu, Yoko Tabe, Maria Rosaria Ricciardi, Chiara Gregorj, Steven J. Collins, Bing Z. Carter, Carmen D'Angelo, Maria Teresa Petrucci, Robin Foà, Francesco Cognetti, Agostino Tafuri, Michael Andreeff

Blood (2006) 109 (5): 2121–2129.

https://doi.org/10.1182/blood-2006-05-024679

Published: 2006

Journal Articles

Effective Targeting of MEK/ERK Signalling at Nanomolar Concentrations by the Novel Small Molecule Inhibitor PD0325901 in Hematopoietic and Solid Tumors.

Maria R. Ricciardi, PhD, Maria C. Scerpa, PhD, Ludovica Ciuffreda, PhD, Sabina Chiaretti, MD, PhD, Simona Tavolaro, PhD, Jacopo Gervasoni, Fabiana De Cave, PhD, Chiara Gregorj, PhD, Maria T. Petrucci, MD, Francesco Cognetti, MD, Michael Andreeff, MD, PhD, Gabriella Zupi, MD, Robin Foà, MD, Agostino Tafuri, MD, Michele Milella, MD

Blood (2005) 106 (11): 3370.

https://doi.org/10.1182/blood.V106.11.3370.3370

Published: 2005

NARROW

Parallel Signaling through PI3K/AKT/mTOR Mediates Resistance to MEK Inhibition in Preclinical Models of Acute Myeloid Leukemia (AML): Synergistic Effects of Combined MEK and mTOR Inhibition.

Development of Mek inhibition (MEK-I)-Based Therapeutic Strategies in Acute Myeloid Leukemia (AML)

Comparative Gene Profiling of Acute Myeloid Leukemia (AML) and Malignant Melanoma (MEL) Cell Lines Exposed to the MEK Inhibitor PD0325901 Reveals Common Effectors of the MEK/ERK Kinase Module.

Molecular and Functional Effects of the Novel MEK Inhibitor PD0325901 in Preclinical Models of Human Leukemias.

MEK blockade converts AML differentiating response to retinoids into extensive apoptosis

Effective Targeting of MEK/ERK Signalling at Nanomolar Concentrations by the Novel Small Molecule Inhibitor PD0325901 in Hematopoietic and Solid Tumors.

Email alerts

ASH Publications

American Society of Hematology

Parallel Signaling through PI3K/AKT/mTOR Mediates Resistance to MEK Inhibition in Preclinical Models of Acute Myeloid Leukemia (AML): Synergistic Effects of Combined MEK and mTOR Inhibition.

Development of Mek inhibition (MEK-I)-Based Therapeutic Strategies in Acute Myeloid Leukemia (AML)

Comparative Gene Profiling of Acute Myeloid Leukemia (AML) and Malignant Melanoma (MEL) Cell Lines Exposed to the MEK Inhibitor PD0325901 Reveals Common Effectors of the MEK/ERK Kinase Module.

Molecular and Functional Effects of the Novel MEK Inhibitor PD0325901 in Preclinical Models of Human Leukemias.

MEK blockade converts AML differentiating response to retinoids into extensive apoptosis

Effective Targeting of MEK/ERK Signalling at Nanomolar Concentrations by the Novel Small Molecule Inhibitor PD0325901 in Hematopoietic and Solid Tumors.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only